QLGN | Qualigen Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.82 - 3.97
52 Week Range	3.34 - 39.15
Beta	-0.01
Implied Volatility	557.36%
IV Rank	60.57%
Day's Volume	5,229
Average Volume	76,621
Shares Outstanding	736,431
Market Cap	2,849,988
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-06-23

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	3,635.00
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	4
Country	USA
Website	QLGN

Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

QLGN's peers: ZVSA, IMMX, PHIO, ATNF, NAVB, ENOB, TCON, ARDS, ENTX, ANEB, ZIVO, INDP, MTCR, ASMB, VRAX, BWV, REVB, HILS, KPRX, SLRX, TMBR, ARTLW, NTRB, ALRN

*Chart delayed

Analyzing fundamentals for QLGN we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see QLGN Fundamentals page.

Watching at QLGN technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on QLGN Technicals page.